VIVUS to Extend Return Date of STENDRA Commercial Rights

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
VIVUS to Extend Return Date of STENDRA Commercial Rights

MOUNTAIN VIEW, CA --(Marketwired - June 30, 2016) - VIVUS, Inc. ( NASDAQ : VVUS ) (the "Company"), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health, today announced an extension of the termination date of the license agreement between Auxilium Pharmaceuticals, Inc., a subsidiary of Endo International, plc, and VIVUS for STENDRA ® (avanafil) U.S. and Canadian commercial rights through August 31, 2016. In December 2015, Auxilium notified VIVUS of its intention to return the U.S. and Canadian commercial rights for STENDRA. This notification was Auxilium's contractually required six-month notice of termination which, absent an agreement between Auxilium and the Company, would have resulted in the termination of the license agreement on June 30, 2016.

"As we have discussed, we and our advisor are engaged in a business evaluation process to optimize the value of STENDRA and Qsymia," said Seth H. Z. Fischer, VIVUS Chief Executive Officer. "We expect to make our decision on whether to commercialize STENDRA on our own or with a third party in the near term. The extension with Auxilium will provide us with additional time to ensure no interruptions in the availability of STENDRA to patients and health care providers while we complete our evaluation and process."

About Avanafil

STENDRA ® (avanafil) is approved in the U.S. by the FDA for the treatment of erectile dysfunction. Auxilium Pharmaceuticals, Inc. has exclusive marketing rights to STENDRA in the U.S. and Canada through August 31, 2016, at which time such rights will revert back to VIVUS.

STENDRA is available through retail and mail order pharmacies.

SPEDRA ™ , the trade name for avanafil in the EU, is approved by the EMA for the treatment of erectile dysfunction in the EU. VIVUS has granted an exclusive license to the Menarini Group through its subsidiary Berlin-Chemie AG to commercialize and promote SPEDRA for the treatment of erectile dysfunction in over 40 European countries plus Australia and New Zealand.

VIVUS has granted an exclusive license to Sanofi to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.

Avanafil is licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. VIVUS is in discussions with other parties for the commercialization rights to its remaining territories.

For more information about STENDRA, please visit www.Stendra.com .

Important Safety Information

STENDRA ® (avanafil) is prescribed to treat erectile dysfunction (ED).

Do not take STENDRA if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure.

Discuss your general health status with your healthcare provider to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.

STENDRA may affect the way other medicines work. Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir ® ), indinavir (Crixivan ® ), saquinavir (Fortavase ® or Invirase ® ) or atazanavir (Reyataz ® ); some types of oral antifungal medicines, such as ketoconazole (Nizoral ® ), and itraconazole (Sporanox ® ); or some types of antibiotics, such as clarithromycin (Biaxin ® ), telithromycin (Ketek ® ), or erythromycin.

In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.

In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including STENDRA) reported a sudden decrease or loss of vision. It is not possible to determine whether these events are related directly to these medicines or to other factors. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including STENDRA, and call a doctor right away.

Sudden decrease or loss of hearing has been rarely reported in people taking PDE5 inhibitors, including STENDRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you experience sudden decrease or loss of hearing, stop taking STENDRA and contact a doctor right away. If you have prostate problems or high blood pressure for which you take medicines called alpha blockers or other anti-hypertensives, your doctor may start you on a lower dose of STENDRA.

Drinking too much alcohol when taking STENDRA may lead to headache, dizziness, and lower blood pressure.

STENDRA in combination with other treatments for ED is not recommended.

STENDRA does not protect against sexually transmitted diseases, including HIV.

The most common side effects of STENDRA are headache, flushing, runny nose and congestion.

Please see full patient prescribing information for STENDRA (50 mg, 100 mg, 200 mg) tablets.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com .

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks, uncertainties and other factors, including risks and uncertainties related to potential change in our business strategy to enhance long-term stockholder value; risks and uncertainties related to the impact of promotional programs for Qsymia on our net product revenue and net income (loss) in future periods; risks and uncertainties related to the impact of the return of the U.S. and Canadian rights for the commercialization of STENDRA; risks and uncertainties related to our ability, either by ourselves or through a third party, to successfully commercialize STENDRA in the U.S. and Canada; risks and uncertainties related to our ability to successfully commercialize Qsymia including risks and uncertainties related to expansion to retail distribution, the broadening of payor reimbursement, the expansion of Qsymia's primary care presence, changing market dynamics shifting prescribing towards obesity specialists, and the outcomes of our discussions with pharmaceutical companies and our strategic and franchise-specific pathways for Qsymia; risks and uncertainties related to our ability to commercialize Qsymia efficiently in 2016; and risks and uncertainties related to our ability to successfully complete on acceptable terms, and on a timely basis, avanafil partnering discussions for territories under our license with MTPC in which we do not have or will be ending a commercial collaboration, including the U.S., Canada and Latin America. These risks and uncertainties could cause actual results to differ materially from those referred to in these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2015 as filed on March 9, 2016 and as amended by the Form 10-K/A filed on April 22, 2016, and periodic reports filed with the Securities and Exchange Commission. VIVUS does not undertake an obligation to update or revise any forward-looking statements.

VIVUS, Inc. Mark Oki Chief Financial Officer oki@vivus.com 650-934-5200 Investor Relations: The Trout Group Brian Korb Managing Director bkorb@troutgroup.com 646-378-2923

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 125

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 92

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 316

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 233

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

BJ's Wholesale Club Exceeds Expectations with Q4 Earnings

Updated Category News Views 131

BJ's Wholesale Club Achieves Impressive Q4 Results BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has delivered a noteworthy performance in its latest financial results, showcasing resilience and growth in a competitive market. The company's fourth-quarter performance has not only exceeded expectations but also highlighted significant strengths in key operational areas....

Continue Reading
Elemeno Health Appoints Tim Coulter as New CEO for Growth

Updated Category News Views 433

Elemeno Health Welcomes Tim Coulter as New CEO Elemeno Health, a leader in microlearning solutions for healthcare staff, has made a significant announcement regarding its leadership. The company is thrilled to introduce Tim Coulter as its new Chief Executive Officer. With an impressive track record spanning over two decades in health technology and enterprise software,...

Continue Reading
Emerging Trends and Insights in the Amber Glass Packaging Market

Updated Category News Views 152

Growth and Innovation in Amber Glass Packaging The global amber glass packaging market has displayed strong resilience and growth potential. Recent studies indicate that this market, valued at USD 8.46 billion, is projected to reach USD 13.15 billion, indicating a robust compound annual growth rate (CAGR). This surge is driven by the multidimensional advantages of amber...

Continue Reading
FiEE, Inc. Celebrates Trading Resumption on Nasdaq as MINM

Updated Category News Views 273

FiEE, Inc. Announces Trading Resumption on Nasdaq The technology-driven company FiEE, Inc. is excited to share that it will resume trading on the Nasdaq under the existing symbol "MINM". This significant milestone follows a successful hearing with the Nasdaq Hearings Panel, which led to the decision to reinstate trading on the Nasdaq Capital Market. Details of the Trading...

Continue Reading
Vera Therapeutics Expands Talent with Inducement Awards

Updated Category News Views 209

Vera Therapeutics Expands Talent with Inducement Awards Vera Therapeutics, Inc. (Nasdaq: VERA) has recently taken a significant step towards enhancing its workforce by granting inducement awards. These awards, which were declared by the Compensation Committee on January 8, have been established to attract and retain six new employees. The inducement awards include a...

Continue Reading